Imperial College London


Faculty of MedicineNational Heart & Lung Institute

Research Associate



+44 (0)20 7594 7790jonathan.baker




223Guy Scadding BuildingRoyal Brompton Campus





Dr Jonathan Baker is a Research Associate at the Airway Disease Section of the National Heart and Lung Institute. His research interests involve investigating aberrant signalling and inflammatory mechanisms in the respiratory disease, chronic obstructive pulmonary disease (COPD). Using diseased and control primary human lung samples Jonathan's work has focussed on understanding cellular senescence in COPD, as well as examining the IL-36 family of cytokines in neutrophilic inflammation in the lung. 

Jonathan studied Biochemistry as an undergraduate at Newcastle University, where he was awarded the Emmerson Biochemistry Research prize for his dissertation. Following the completion of his BSc, he continued his studies at Newcastle University, obtaining his PhD in 2014. During his PhD he studied the family of kinases, named Protein Kinase D, in the regulation of matrix metalloproteinase expression in osteoarthritis. This work was presented at the BSR in Birmingham, in which he was awarded their Young Investigator award.    

After completion of his PhD Jonathan started working for Professor Peter Barnes and Dr Kaz Ito at the NHLI. During this time Jonathan studied the role of miRNAs in the regulation of sirtuin-1 and sirtuin-6, understanding the molecular mechanism which lead to the down-regulation of these putative anti-ageing proteins in patients with COPD. This work focussed  on understanding the mechanism(s) which drive cellular senescence and the potential use of senolytics and senomorphic drugs in the treatment of COPD. 

Jonathan then joined Professor Louise Donnelly research group, where he began examining the role of IL-36 cytokines in COPD. Jonathan's current work has suggested the importance of these cytokines in driving neutrophilic inflammation in the COPD lung and that targeting IL-36 cytokines may be a therapeutic intervention for COPD. 

Jonathan assists in the supervision of PhD, MRes, and BSc students and is a member of the American Thoracic Society, European Respiratory Society, and the British Association for Lung Research.



Koss CK, Wohnhaas CT, Baker JR, et al., 2021, IL36 is a critical upstream amplifier of neutrophilic lung inflammation in mice, Communications Biology, Vol:4, ISSN:2399-3642, Pages:1-15

Baker JR, Donnelly LE, 2021, Leukocyte function in COPD: clinical relevance and potential for drug therapy., The International Journal of Chronic Obstructive Pulmonary Disease, Vol:16, ISSN:1176-9106, Pages:2227-2242

Ramakrishnan S, Nicolau DV, Langford B, et al., 2021, Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, Lancet Respiratory Medicine, Vol:9, ISSN:2213-2600, Pages:763-772

Ritchie AI, Baker JR, Parekh TM, et al., 2021, Update in Chronic Obstructive Pulmonary Disease 2020, American Journal of Respiratory and Critical Care Medicine, Vol:204, ISSN:1073-449X, Pages:14-22

Kono Y, Colley T, To M, et al., 2021, Cigarette smoke-induced impairment of autophagy in macrophages increases galectin-8 and inflammation, Scientific Reports, Vol:11, ISSN:2045-2322

More Publications